Purinergic regulation of the immune system

Nature Reviews Immunology

Volumn 16, Issue 3, 2016, Pages 177-192

  Cekic, Caglar ^a   Linden, Joel ^b  

^a BILKENT UNIVERSITY   (Turkey)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; NUCLEOTIDE; PURINERGIC P2 RECEPTOR; PURINERGIC P2X RECEPTOR; PURINERGIC P2Y RECEPTOR; PURINE DERIVATIVE;

AUTOIMMUNITY; EFFECTOR CELL; EXTRACELLULAR SPACE; GRAFT REJECTION; HEART MUSCLE ISCHEMIA; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; KIDNEY ISCHEMIA; MACROPHAGE; MONOCYTE; NATURAL KILLER T CELL; NEOPLASM; NEUTROPHIL; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TISSUE INJURY; TISSUE REACTION; ADAPTIVE IMMUNITY; ANIMAL; HUMAN; IMMUNOLOGY; INNATE IMMUNITY;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; PURINES; SIGNAL TRANSDUCTION;

EID: 84959559428     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri.2016.4     Document Type: Review

References (209)

1. Kumar A., Sharma R., Kamaluddin. Formamide-based synthesis of nucleobases by metal(II) octacyanomolybdate(IV): implication in prebiotic chemistry. Astrobiology. 14, 769-779 (2014).
2. Verkhratsky A, & Burnstock G. Biology of purinergic signalling: its ancient evolutionary roots, its omnipresence and its multiple functional significance. Bioessays. 36, 697-705 (2014).
3. Surprenant A, & North R. A. Signaling at purinergic P2X receptors. Annu. Rev. Physiol. 71, 333-359 (2009).
4. Jacobson K. A. Structure-based approaches to ligands for G protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates. J. Med. Chem. 56, 3749-3767 (2013).
5. Chekeni F. B, et al. Pannexin 1 channels mediate 'find me' signal release and membrane permeability during apoptosis. Nature. 467, 863-867 (2010).
6. Pelegrin P, & Surprenant A. The P2X7 receptor-pannexin connection to dye uptake and IL 1β release. Purinergic Signal. 5, 129-137 (2009).
7. Poon I. K, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature. 507, 329-334 (2014).
8. Shatarat A., Dunn W. R, & Ralevic V. Raised tone reveals ATP as a sympathetic neurotransmitter in the porcine mesenteric arterial bed. Purinergic Signal. 10, 639-649 (2014).
9. Falker K., Lange D, & Presek P. P2Y12 ADP receptor-dependent tyrosine phosphorylation of proteins of 27 and 31 kDa in thrombin-stimulated human platelets. Thromb. Haemostasis. 93, 880-888 (2005).
10. Gao Z. G., Wei Q., Jayasekara M. P, & Jacobson K. A. The role of P2Y14 and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal. 9, 31-40 (2013).
11. Asgari E, et al. C3a modulates IL 1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. Blood. 122, 3473-3481 (2013).
12. Ayna G, et al. ATP release from dying autophagic cells and their phagocytosis are crucial for inflammasome activation in macrophages. PloS ONE 7, e40069 (2012).
13. Junger W. G. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11, 201-212 (2011).
14. Horenstein A. L, et al. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives anovel adenosinergic loop in human T lymphocytes. Oncoimmunology 2, e26246 (2013).
15. Langer D, et al. Distribution of ectonucleotidases in the rodent brain revisited. Cell Tissue Res. 334, 199-217 (2008).
16. Jin X., Shepherd R. K., Duling B. R, & Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J. Clin. Invest. 100, 2849-2857 (1997).
17. Baldwin S. A, et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Archiv. 447, 735-743 (2004).
18. Gray J. H., Owen R. P, & Giacomini K. M. The concentrative nucleoside transporter family, SLC28. Pflugers Archiv. 447, 728-734 (2004).
19. Eltzschig H. K, et al. Central role of Sp1 regulated CD39 in hypoxia/ischemia protection. Blood. 113, 224-232 (2009).
20. Diaz-Hernandez M, et al. Inhibition of the ATP-gated P2X7 receptor promotes axonal growth and branching in cultured hippocampal neurons. J. Cell Sci. 121, 3717-3728 (2008).
21. Bele T, & Fabbretti E. P2X receptors, sensory neurons and pain. Curr. Med. Chem. 22, 845-850 (2015).
22. Zimmermann H. Extracellular ATP and other nucleotides-ubiquitous triggers of intercellular messenger release. Purinergic Signal. http://dx.doi.org/ 10.1007/s11302-015-9483-2 (2015).
23. Sandilos J. K, et al. Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-Associated C terminal autoinhibitory region. J. Biol. Chem. 287, 11303-11311 (2011).
24. Haas M., Shaaban A, & Reiser G. Alanine-(87)-Threonine polymorphism impairs signaling and internalization of the human P2Y11 receptor, when co expressed with the P2Y1 receptor. J. Neurochem. 129, 602-613 (2014).
25. Chen Y, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 314, 1792-1795 (2006).
26. Barrett M. O, et al. A selective high-Affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol. Pharmacol. 84, 41-49 (2013).
27. Ohta A, & Sitkovsky M. Role of G protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414, 916-920 (2001).
28. Eckle T, et al. Identification of hypoxia-inducible factor HIF 1A as transcriptional regulator of the A2B adenosine receptor during acute lung injury. J. Immunol. 192, 1249-1256 (2014).
29. Linden J., Thai T., Figler H., Jin X, & Robeva A. S. Characterization of human A2B adenosine receptors: radioligand binding, western blotting, and coupling to Gq in human embryonic kidney 293 cells and HMC 1 mast cells. Mol. Pharmacol. 56, 705-713 (1999).
30. Sorrentino C., Miele L., Porta A., Pinto A, & Morello S. Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget. 6, 27478-27489 (2015).
31. Zhou Y, et al. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J. Immunol. 186, 1097-1106 (2011).
32. Wilson J. M, et al. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL 6. J. Immunol. 186, 6746-6752 (2011).
33. Resta R, et al. Insights into thymic purine metabolism and adenosine deaminase deficiency revealed by transgenic mice overexpressing ecto 5? nucleotidase (CD73). J. Clin. Invest. 99, 676-683 (1997).
34. Lepine S., Le Stunff H., Lakatos B., Sulpice J. C, & Giraud F. ATP-induced apoptosis of thymocytes is mediated by activation of P2X7 receptor and involves de novo ceramide synthesis and mitochondria. Biochim. Biophys. Acta. 1761, 73-82 (2006).
35. Cekic C., Sag D., Day Y. J, & Linden J. Extracellular adenosine regulates naive T cell development and peripheral maintenance. J. Exp. Med. 210, 2693-2706 (2013).
36. Woehrle T, et al. Pannexin 1 hemichannel-mediated ATP release together with P2X1 and P2X4 receptors regulate T cell activation at the immune synapse. Blood. 116, 3475-3484 (2010).
37. Wang L., Jacobsen S. E., Bengtsson A, & Erlinge D. P2 receptor mRNA expression profiles in human lymphocytes, monocytes and CD34+ stem and progenitor cells. BMC Immunol. 5, 16 (2004).
38. Romio M, et al. Extracellular purine metabolism and signaling of CD73 derived adenosine in murine TReg and Teff cells. Am. J. Physiol. Cell Physiol. 301, C530-C539 (2011).
39. Vang T, et al. Activation of the COOH-Terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J. Exp. Med. 193, 497-507 (2001).
40. Linnemann C, et al. Adenosine regulates CD8 T cell priming by inhibition of membrane-proximal T cell receptor signalling. Immunology 128, e728-e737 (2009).
41. Raskovalova T, et al. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8+ and CD4+ T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res. 67, 5949-5956 (2007).
42. Su Y., Jackson E. K, & Gorelik E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol. Immunother. 60, 111-122 (2011).
43. Sullivan G. W., Carper H. T, & Mandell G. L. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-α-primed neutrophil oxidative activity. Int. J. Immunopharmacol. 17, 793-803 (1995).
44. Wittmann M, & Helliwell P. S. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol. Ther. 3, 1-15 (2013).
45. Chimote A. A, et al. Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells. J. Immunol. 191, 6273-6280 (2013).
46. Zhang H, et al. Adenosine acts through A2 receptors to inhibit IL 2 induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3?,5? monophosphate and phosphatases. J. Immunol. 173, 932-944 (2004).
47. Butler J. J, et al. Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co stimulatory molecules: role of interleukin 2 and cyclic AMP signaling pathways. J. Cell. Biochem. 89, 975-991 (2003).
48. Parry R. V., Harris S. J, & Ward S. G. Fine tuning T lymphocytes: a role for the lipid phosphatase SHIP 1. Biochim. Biophys. Acta. 1804, 592-597 (2010).
49. Palmer D. C, & Restifo N. P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 30, 592-602 (2009).
50. Raskovalova T., Lokshin A., Huang X., Jackson E. K, & Gorelik E. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL 2/ NKp46 activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol. Res. 36, 91-99 (2007).
51. Deaglio S, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
52. Schenk U, et al. ATP Inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors. Science signaling 4, ra12 (2011).
53. Piconese S, et al. Mast cells counteract regulatory T cell suppression through interleukin 6 and OX40/ OX40L axis toward Th17 cell differentiation. Blood. 114, 2639-2648 (2009).
54. Rissiek B., Haag F., Boyer O., Koch-Nolte F, & Adriouch S. ADP-ribosylation of P2X7: a matter of life and death for regulatory T cells and natural killer T cells. Curr. Top. Microbiol. Immunol. 384, 107-126 (2015).
55. Ohta A, & Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Frontiers Immunol. 5, 304 (2014).
56. Kinsey G. R, et al. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J. Am. Soc. Nephrol. 23, 1528-1537 (2012).
57. Smyth L. A, et al. CD73 expression on extracellular vesicles derived from CD4+ CD25+ Foxp3+ T cells contributes to their regulatory function. Eur. J. Immunol. 43, 2430-2440 (2013).
58. Saldanha-Araujo F, et al. Mesenchymal stromal cells up regulate CD39 and increase adenosine production to suppress activated T lymphocytes. Stem Cell Res. 7, 66-74 (2011).
59. Mandapathil M., Lang S., Gorelik E, & Whiteside T. L. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J. Immunol. Methods. 346, 55-63 (2009).
60. Nikolova M, et al. CD39/adenosine pathway is involved in AIDS progression. PLoS Pathog. 7, e1002110 (2011).
61. Borsellino G, et al. Expression of ectonucleotidase CD39 by Foxp3+ TReg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 110, 1225-1232 (2007).
62. Dwyer K. M, et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am. J. Transplant. 10, 2410-2420 (2010).
63. Jenabian M. A, et al. Regulatory T cells negatively affect IL 2 production of effector T cells through CD39/ adenosine pathway in HIV infection. PLoS Pathog. 9, e1003319 (2013).
64. Reilly E. C., Wands J. R, & Brossay L. Cytokine dependent and independent iNKT cell activation. Cytokine. 51, 227-231 (2010).
65. Araki M., Miyake S, & Yamamura T. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy. Curr. Med. Chem. 15, 2337-2345 (2008).
66. Beldi G, et al. Natural killer T cell dysfunction in CD39 null mice protects against concanavalin A induced hepatitis. Hepatology. 48, 841-852 (2008).
67. Lappas C. M., Day Y. J., Marshall M. A., Engelhard V. H, & Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d dependent NKT cell activation. J. Exp. Med. 203, 2639-2648 (2006).
68. Linden J, & Cekic C. Regulation of lymphocyte function by adenosine. Arterioscler. Thromb. Vasc. Biol. 32, 2097-2103 (2012).
69. Nowak-Machen M, et al. Pulmonary natural killer T cells play an essential role in mediating hyperoxic acute lung injury. Am. J. Respir. Cell Mol. Biol. 48, 601-609 (2013).
70. Brennan P. J, et al. Activation of iNKT cells by a distinct constituent of the endogenous glucosylceramide fraction. Proc. Natl Acad. Sci. USA. 111, 13433-13438 (2014).
71. Wallace K. L, et al. NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-? and CXCR3 chemokines. Blood. 114, 667-676 (2009).
72. Uzar E, et al. The activity of adenosine deaminase and the level of nitric oxide in spinal cord of methotrexate administered rats: protective effect of caffeic acid phenethyl ester. Toxicology. 218, 125-133 (2006).
73. Nowak M, et al. The A2aR adenosine receptor controls cytokine production in iNKT cells. Eur. J. Immunol. 40, 682-687 (2010).
74. Cao Z, et al. Preactivation of NKT cells with α-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL 13 and adenosine A2A receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 297, G249-G258 (2009).
75. Wallace K. L, & Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 116, 5010-5020 (2010).
76. Field J. J, et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood. 121, 3329-3334 (2013).
77. Elliott M. R, et al. Nucleotides released by apoptotic cells act as a find me signal to promote phagocytic clearance. Nature. 461, 282-286 (2009).
78. Aymeric L, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res. 70, 855-858 (2010).
79. Gessi S, et al. Adenosine modulates HIF 1α, VEGF, IL 8, and foam cell formation in a human model of hypoxic foam cells. Arterioscler. Thromb. Vasc. Biol. 30, 90-97 (2010).
80. Ryzhov S, et al. Effect of A2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J. Pharmacol. Exp. Ther. 324, 694-700 (2008).
81. Cekic C., Day Y. J., Sag D, & Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 74, 7250-7259 (2014).
82. Ferrante C. J, et al. The adenosine-dependent angiogenic switch of macrophages to an M2 like phenotype is independent of interleukin 4 receptor α (IL 4Rα) signaling. Inflammation. 36, 921-931 (2013).
83. Garcia G. E, et al. Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis. FASEB J. 22, 445-454 (2008).
84. Majumdar S, & Aggarwal B. B. Adenosine suppresses activation of nuclear factor-?B selectively induced by tumor necrosis factor in different cell types. Oncogene. 22, 1206-1218 (2003).
85. Fotheringham J., Mayne M., Holden C., Nath A, & Geiger J. D. Adenosine receptors control HIV 1 Tat-induced inflammatory responses through protein phosphatase. Virology. 327, 186-195 (2004).
86. Elson G, et al. Induction of murine adenosine A2A receptor expression by LPS: analysis of the 5' upstream promoter. Genes Immun. 14, 147-153 (2013).
87. He X, et al. A feedback loop in PPAR?-Adenosine A2A receptor signaling inhibits inflammation and attenuates lung damages in a mouse model of LPS-induced acute lung injury. Cell Signal. 25, 1913-1923 (2013).
88. Murphree L. J., Sullivan G. W., Marshall M. A, & Linden J. Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF ?B in A2A adenosine receptor induction. Biochem. J. 391, 575-580 (2005).
89. Heyn J, et al. Adenosine A2A Receptor Upregulation in Human PMNs Is Controlled by MiRNA 214, MiRNA 15, and MiRNA 16. Shock. 37, 156-163 (2012).
90. Duro E., Pallai A., Koroskenyi K., Sarang Z, & Szondy Z. Adenosine A3 receptors negatively regulate the engulfment-dependent apoptotic cell suppression of inflammation. Immunol. Lett. 162, 292-301 (2014).
91. Li L, et al. Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury. J. Clin. Invest. 122, 3931-3942 (2012).
92. Liu C, et al. Adenosine A2A receptor, a potential valuable target for controlling reoxygenated DCs-Triggered inflammation. Mol. Immunol. 63, 559-565 (2015).
93. Panther E, et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T cell stimulatory capacity of human dendritic cells. Blood. 101, 3985-3990 (2003).
94. Ring S, et al. Regulatory T cell-derived adenosine induces dendritic cell migration through the Epac Rap1 pathway. J. Immunol. 194, 3735-3744 (2015).
95. Hofer S, et al. Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. J. Investigative Dermatol. 121, 300-307 (2003).
96. Panther E, et al. Expression and function of adenosine receptors in human dendritic cells. FASEB J. 15, 1963-1970 (2001).
97. Schnurr M, et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood. 103, 1391-1397 (2004).
98. Novitskiy S. V, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 112, 1822-1831 (2008).
99. Ben Addi A, et al. Modulation of murine dendritic cell function by adenine nucleotides and adenosine: involvement of the A2B receptor. Eur. J. Immunol. 38, 1610-1620 (2008).
100. Figueiredo A. B., Serafim T. D., Marques-da Silva E. A., Meyer-Fernandes J. R, & Afonso L. C. Leishmania amazonensis impairs DC function by inhibiting CD40 expression via A2B adenosine receptor activation. Eur. J. Immunol. 42, 1203-1215 (2012).
101. Wilson J. M, et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J. Immunol. 182, 4616-4623 (2009).
102. Yang M, et al. HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2 stimulating phenotype under hypoxia. Immunol. Cell Biol. 88, 165-171 (2010).
103. Martin M., Huguet J., Centelles J. J, & Franco R. Expression of ecto-Adenosine deaminase and CD26 in human T cells triggered by the TCR CD3 complex. Possible role of adenosine deaminase as costimulatory molecule. J. Immunol. 155, 4630-4643 (1995).
104. Martinez-Navio J. M, et al. Adenosine deaminase potentiates the generation of effector, memory, and regulatory CD4+ T cells. J. Leukocyte Biol. 89, 127-136 (2011).
105. Pacheco R, et al. CD26, adenosine deaminase, and adenosine receptors mediate costimulatory signals in the immunological synapse. Proc. Natl Acad. Sci. USA. 102, 9583-9588 (2005).
106. Gilles S, et al. Pollen metabolome analysis reveals adenosine as a major regulator of dendritic cell-primed TH cell responses. J. Allergy Clin. Immunol. 127, 454-461 (2011).
107. Cekic C, et al. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J. Immunol. 188, 198-205 (2012).
108. Inoue Y., Chen Y., Hirsh M. I., Yip L, & Junger W. G. A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock. 30, 173-177 (2008).
109. Moore C. C, et al. An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect. Dis. 8, 141 (2008).
110. Griffin G. K, et al. IL 17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J. Immunol. 188, 6287-6299 (2012).
111. Reutershan J., Cagnina R. E., Chang D., Linden J, & Ley K. Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J. Immunol. 179, 1254-1263 (2007).
112. Sullivan G. W., Rieger J. M., Scheld W. M., Macdonald T. L, & Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2 propynylcyclohexyl adenosine A2A receptor agonists. Br. J. Pharmacol. 132, 1017-1026 (2001).
113. Sullivan G. W, et al. Activation of A2A adenosine receptors inhibits expression of α4/β1 integrin (very late antigen 4) on stimulated human neutrophils. J. Leukocyte Biol. 75, 127-134 (2004).
114. Roberts V. S., Cowan P. J., Alexander S. I., Robson S. C, & Dwyer K. M. The role of adenosine receptors A2A and A2B signaling in renal fibrosis. Kidney Int. 86, 685-692 (2014).
115. Zhang H, et al. Blockade of A2B adenosine receptor reduces left ventricular dysfunction and ventricular arrhythmias 1 week after myocardial infarction in the rat model. Heart Rhythm. 11, 101-109 (2014).
116. Wen J, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 24, 740-749 (2010).
117. Mizumura T., Auchampach J. A., Linden J., Bruns R. F, & Gross G. J. PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs. Circ. Res. 79, 415-423 (1996).
118. Maas J. E., Wan T. C., Figler R. A., Gross G. J, & Auchampach J. A. Evidence that the acute phase of ischemic preconditioning does not require signaling by the A 2B adenosine receptor. J. Mol. Cell. Cardiol. 49, 886-893 (2010).
119. Yang Z, et al. Infarct-sparing effect of A2A adenosine receptor activation is due primarily to its action on lymphocytes. Circulation. 111, 2190-2197 (2005).
120. Yang Z, et al. Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 114, 2056-2064 (2006).
121. Tian Y., Marshall M., French B. A., Linden J, & Yang Z. The infarct-sparing effect of IB MECA against myocardial ischemia/reperfusion injury in mice is mediated by sequential activation of adenosine A3 and A 2A receptors. Bas. Res. Cardiol. 110, 16 (2015).
122. Micari A, et al. Improvement in microvascular reflow and reduction of infarct size with adenosine in patients undergoing primary coronary stenting. Am. J. Cardiol. 96, 1410-1415 (2005).
123. Blume C, et al. Autoimmunity in CD73/ Ecto 5? nucleotidase deficient mice induces renal injury. PloS ONE 7, e37100 (2012).
124. Park S. W, et al. A1 adenosine receptor allosteric enhancer PD 81723 protects against renal ischemia-reperfusion injury. Am. J. Physiol. Renal Physiol. 303, F721-F732 (2012).
125. Kim M, et al. Kidney-specific reconstitution of the A1 adenosine receptor in A1 adenosine receptor knockout mice reduces renal ischemia-reperfusion injury. Kidney Int. 75, 809-823 (2009).
126. Lee H. T., Gallos G., Nasr S. H, & Emala C. W. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J. Am. Soc. Nephrol. 15, 102-111 (2004).
127. Garcia G. E., Truong L. D., Chen J. F., Johnson R. J, & Feng L. Adenosine A2A receptor activation prevents progressive kidney fibrosis in a model of immune-Associated chronic inflammation. Kidney Int. 80, 378-388 (2011).
128. Awad A. S, et al. Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 290, F828-F837 (2006).
129. Okusa M. D., Linden J., Macdonald T, & Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am. J. Physiol. 277, F404-F412 (1999).
130. Duhant X, et al. Extracellular adenine nucleotides inhibit the activation of human CD4+ T lymphocytes. J. Immunol. 169, 15-21 (2002).
131. Grenz A, et al. Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release. J. Immunol. 189, 4566-4573 (2012).
132. Grenz A, et al. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med. 5, e137 (2008).
133. Joo J. D, et al. Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors. Am. J. Physiol. Renal Physiol. 293, F1847-F1857 (2007).
134. Folkesson H. G., Kuzenko S. R., Lipson D. A., Matthay M. A, & Simmons M. A. The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats. Am. J. Physiol. Lung Cell. Mol. Physiol. 303, L259-L271 (2012).
135. Gazoni L. M, et al. Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. J. Thorac. Cardiovasc. Surg. 140, 440-446 (2010).
136. Schingnitz U, et al. Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury. J. Immunol. 184, 5271-5279 (2010).
137. Ohta A, et al. In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br. J. Pharmacol. 156, 297-306 (2009).
138. Sharma A. K, et al. Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J. Thorac. Cardiovascular Surg. 139, 474-482 (2010).
139. Karmouty-Quintana H, et al. Adenosine A2B receptor and hyaluronan modulate pulmonary hypertension associated with chronic obstructive pulmonary disease. Am. J. Respiratory Cell. Mol. Biol. 49, 1038-1047 (2013).
140. Belikoff B. G., Vaickus L. J., Sitkovsky M, & Remick D. G. A2B adenosine receptor expression by myeloid cells is proinflammatory in murine allergic-Airway inflammation. J. Immunol. 189, 3707-3713 (2012).
141. Ryzhov S., Goldstein A. E., Biaggioni I, & Feoktistov I. Cross-Talk between Gs-And Gq-coupled pathways in regulation of interleukin 4 by A2B adenosine receptors in human mast cells. Mol. Pharmacol. 70, 727-735 (2006).
142. Karmouty-Quintana H, et al. Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J. 29, 50-60 (2015).
143. Le T. T, et al. Blockade of IL 6 trans signaling attenuates pulmonary fibrosis. J. Immunol. 193, 3755-3768 (2014).
144. Vergani A, et al. Effect of the purinergic inhibitor oxidized ATP in a model of islet allograft rejection. Diabetes. 62, 1665-1675 (2013).
145. Lang P. A, et al. Oxidized ATP inhibits T cell-mediated autoimmunity. Eur. J. Immunol. 40, 2401-2408 (2010).
146. Ohta A, et al. The development and immunosuppressive functions of CD4+CD25+FoxP3+ regulatory T cells are under influence of the adenosine A2A adenosine receptor pathway. Frontiers Immunol. 3, 190 (2012).
147. Kurtz C. C, et al. Extracellular adenosine regulates colitis through effects on lymphoid and nonlymphoid cells. Am. J. Physiol. Gastrointest. Liver Physiol. 307, G338-G346 (2014).
148. Naganuma M, et al. Cutting edge: critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J. Immunol. 177, 2765-2769 (2006).
149. Odashima M, et al. Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology. 129, 26-33 (2005).
150. Han K. L, et al. Adenosine A2A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease. J. Immunol. 190, 458-468 (2013).
151. Zhang L, et al. Adenosine 2A receptor is protective against renal injury in MRL/lpr mice. Lupus. 20, 667-677 (2011).
152. Mills J. H, et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA. 105, 9325-9330 (2008).
153. Liang D, et al. Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent. J. Immunol. 193, 5498-5505 (2014).
154. Liang D, et al. Roles of the adenosine receptor and CD73 in the regulatory effect of ?d T cells. PLoS ONE 9, e108932 (2014).
155. Lee D. J, & Taylor A. W. Both MC5r and A2Ar are required for protective regulatory immunity in the spleen of post-experimental autoimmune uveitis in mice. J. Immunol. 191, 4103-4111 (2013).
156. Mills J. H., Kim D. G., Krenz A., Chen J. F, & Bynoe M. S. A2A adenosine receptor signaling in lymphocytes and the central nervous system regulates inflammation during experimental autoimmune encephalomyelitis. J. Immunol. 188, 5713-5722 (2012).
157. Wei W, et al. Blocking A2B adenosine receptor alleviates pathogenesis of experimental autoimmune encephalomyelitis via inhibition of IL 6 production and Th17 differentiation. J. Immunol. 190, 138-146 (2013).
158. Beavis P. A, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl Acad. Sci. USA. 110, 14711-14716 (2013).
159. Hatfield S. M, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl Med. 7, 277ra230 (2015).
160. Mittal D, et al. Antimetastatic effects of blocking PD 1 and the adenosine A2A receptor. Cancer Res. 74, 3652-3658 (2014).
161. Leone R. D., Lo Y. C, & Powell J. D. A2aR antagonists: next generation checkpoint blockade for cancer immunotherapy. Comput. Struct. Biotechnol. J. 13, 265-272 (2015).
162. Stagg J, et al. Anti CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA. 107, 1547-1552 (2010).
163. Waickman A. T, et al. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol. Immunother. 61, 917-926 (2012).
164. Beavis P. A, et al. Adenosine receptor 2A blockade increases the efficacy of anti pd 1 through enhanced antitumor t cell responses. Cancer Immunol. Res. 3, 506-517 (2015).
165. Burghoff S, et al. Growth and metastasis of B16 F10 melanoma cells is not critically dependent on host CD73 expression in mice. BMC Cancer. 14, 898 (2014).
166. Amarnath S, et al. Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivo. Stem Cells. 33, 1200-1212 (2015).
167. Sattler C, et al. Inhibition of T cell proliferation by murine multipotent mesenchymal stromal cells is mediated by CD39 expression and adenosine generation. Cell Transplant. 20, 1221-1230 (2011).
168. Hausler S. F, et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 60, 1405-1418 (2011).
169. Takedachi M, et al. CD73 generated adenosine restricts lymphocyte migration into draining lymph nodes. J. Immunol. 180, 6288-6296 (2008).
170. Clayton A., Al Taei S., Webber J., Mason M. D, & Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J. Immunol. 187, 676-683 (2011).
171. Allard B., Turcotte M, & Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin. Ther. Targets. 18, 863-881 (2014).
172. Ohta A, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl Acad. Sci. USA. 103, 13132-13137 (2006).
173. Cekic C, & Linden J. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res. 74, 7239-7249 (2014).
174. Singh V., Ji Q., Feigenbaum L., Leighty R. M, & Hurwitz A. A. Melanoma progression despite infiltration by in vivo-primed TRP 2 specific T cells. J. Immunother. 32, 129-139 (2009).
175. Zhu Z, et al. High-Avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res. 73, 595-604 (2013).
176. Ntantie E, et al. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci. Signal. 6, ra39 (2013).
177. Adinolfi E, et al. Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7. Cancer Res. 75, 635-644 (2015).
178. Di V. irgilio F. Purines, purinergic receptors, and cancer. Cancer Res. 72, 5441-5447 (2012).
179. Awad M. M, & Shaw A. T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin. Adv. Hematol. Oncol. 12, 429-439 (2014).
180. Wilson F. H, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 27, 397-408 (2015).
181. Martini C, et al. A2 adenosine receptors in neutrophils from healthy volunteers and patients with rheumatic disease. Adv. Exp. Med. Biol. 309A, 459-462 (1991).
182. Varani K., Gessi S., Dalpiaz A, & Borea P. A. Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding. Br. J. Pharmacol. 117, 1693-1701 (1996).
183. Hasko G., Linden J., Cronstein B, & Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat. Rev. Drug Discov. 7, 759-770 (2008).
184. Auchampach J. A., Jin X., Wan T. C., Caughey G. H, & Linden J. Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mol. Pharmacol. 52, 846-860 (1997).
185. van der Hoeven D., Wan T. C, & Auchampach J. A. Activation of the A3 adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. Mol. Pharmacol. 74, 685-696 (2008).
186. Ramkumar V., Stiles G. L., Beaven M. A, & Ali H. The A3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 268, 16887-16890 (1993).
187. Sullivan G. W., Linden J., Buster B. L, & Scheld W. M. Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J. Infect. Dis. 180, 1550-1560 (1999).
188. Mediero A., Perez-Aso M., Wilder T, & Cronstein B. N. Methotrexate prevents wear particle-induced inflammatory osteolysis via activation of the adenosine A receptor. Arthritis Rheumatol. 67, 849-555 (2014).
189. Kalvegren H., Fridfeldt J, & Bengtsson T. The role of plasma adenosine deaminase in chemoattractant-stimulated oxygen radical production in neutrophils. Eur. J. Cell Biol. 89, 462-467 (2010).
190. Sluyter R., Barden J. A, & Wiley J. S. Detection of P2X purinergic receptors on human B lymphocytes. Cell Tissue Res. 304, 231-236 (2001).
191. Pupovac A., Geraghty N. J., Watson D, & Sluyter R. Activation of the P2X7 receptor induces the rapid shedding of CD23 from human and murine B cells. Immunol. Cell Biol. 93, 77-85 (2015).
192. Bulanova E, et al. ATP induces P2X7 receptor-independent cytokine and chemokine expression through P2X1 and P2X3 receptors in murine mast cells. J. Leukoc. Biol. 85, 692-702 (2009).
193. Cheng R. D., Ren J. J., Zhang Y. Y, & Ye X. M. P2X4 receptors expressed on microglial cells in post-ischemic inflammation of brain ischemic injury. Neurochem. Int. 67, 9-13 (2014).
194. Wareham K., Vial C., Wykes R. C., Bradding P, & Seward E. P. Functional evidence for the expression of P2X1, 2X4 and P2X7 receptors in human lung mast cells. Br. J. Pharmacol. 157, 1215-1224 (2009).
195. Overes I. M, et al. Expression of P2X5 in lymphoid malignancies results in LRH 1 specific cytotoxic T cell-mediated lysis. Br. J. Haematol. 141, 799-807 (2008).
196. Abramowski P., Ogrodowczyk C., Martin R, & Pongs O. A truncation variant of the cation channel P2RX5 is upregulated during T cell activation. PloS ONE 9, e104692 (2014).
197. Tsukimoto M., Tokunaga A., Harada H, & Kojima S. Blockade of murine T cell activation by antagonists of P2Y6 and P2X7 receptors. Biochem. Biophys. Res. Commun. 384, 512-518 (2009).
198. Yu Q, et al. Expression of P2X6 receptors in the enteric nervous system of the rat gastrointestinal tract. Histochem. Cell Biol. 133, 177-188 (2010).
199. Xiang Z, et al. Expression of P2X receptors on immune cells in the rat liver during postnatal development. Histochem. Cell Biol. 126, 453-463 (2006).
200. Pelegrin P., Barroso-Gutierrez C, & Surprenant A. P2X7 receptor differentially couples to distinct release pathways for IL 1β in mouse macrophage. J. Immunol. 180, 7147-7157 (2008).
201. He Y., Franchi L, & Nunez G. TLR agonists stimulate Nlrp3 dependent IL 1β production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J. Immunol. 190, 334-339 (2013).
202. Gicquel T, et al. IL 1β production is dependent on the activation of purinergic receptors and NLRP3 pathway in human macrophages. FASEB J. 29, 4162-4173 (2015).
203. Nylander S., Mattsson C., Ramstrom S, & Lindahl T. L. The relative importance of the ADP receptors, P2Y12 and P2Y1, in thrombin-induced platelet activation. Thromb. Res. 111, 65-73 (2003).
204. Li H. Q, et al. P2Y4 receptor-mediated pinocytosis contributes to amyloid β-induced self-uptake by microglia. Mol. Cell. Biol. 33, 4282-4293 (2013).
205. Jin J., Dasari V. R., Sistare F. D, & Kunapuli S. P. Distribution of P2Y receptor subtypes on haematopoietic cells. Br. J. Pharmacol. 123, 789-794 (1998).
206. Kimura T, et al. Responses of macrophages to the danger signals released from necrotic cells. Int. Immunol. 26, 697-704 (2014).
207. Moreschi I, et al. NAADP+ is an agonist of the human P2Y11 purinergic receptor. Cell Calcium. 43, 344-355 (2008).
208. Wang L, et al. ADP acting on P2Y13 receptors is a negative feedback pathway for ATP release from human red blood cells. Circul. Res. 96, 189-196 (2005).
209. Dal Ben D, et al. Purinergic P2X receptors: structural models and analysis of ligand-Target interaction. Eur. J. Med. Chem. 89, 561-580 (2015).